Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem

Abstract

Elderly patients with advanced HCC, when treated with sorafenib, have an equivalent clinical outcome with similar toxicity rates as their younger counterparts. Age alone should not be a discriminating factor for the management of advanced HCC with sorafenib.